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Outcomes of nonmyeloablative (NMA), HLA-haploidentical (haplo), related-donor allogeneic blood or marrow
transplantation (allo-BMT) with high-dose post-transplantation cyclophosphamide (PTCy) appear to be similar
to those using HLA-matched donors. Thus, it may be possible to prioritize donor factors other than HLA
matching that could enhance antitumor activity. The Fc receptor polymorphism FCGR3A-158VV may confer
greater sensitivity to rituximab than FCGR3A-158FF. In a prospective phase II study of NMA, related-donor allo-
BMT with PTCy and post-transplantation rituximab for patients with B cell lymphomas, we hypothesized that
donor selection that prioritized FCGR3A-158 polymorphism over HLA matching would be feasible, safe, and
improve outcomes. The primary endpoint was 1-year progression-free survival (PFS). Of 83 patients trans-
planted (median age, 59 years), 69 (83%) received haplo grafts. Fifty-four (65%) received a graft that maintained
or improved their Fc receptor polymorphism status. With 2.6-year median follow-up, the 1-year PFS and overall
survival (OS) probabilities were 71% and 86%, respectively, with 1-year relapse and nonrelapse mortality (NRM)
probabilities of 20% and 8%. At 1 year, the probability of acute grades II to IV graft-versus-host disease (GVHD)
was 41%, with acute grades III to IV GVHD probability of 5% and chronic GVHD probability of 11%. Among haplo
transplants, the 1-year probabilities of PFS, OS, relapse, and NRM were 70%, 83%, 20%, and 10%, respectively. No
differences in outcomes were observed based on donor FCGR3A-158 polymorphism. Excess infection risk was
not apparent with post-transplantation rituximab. Although donor selection based on FCGR3A-158 poly-
morphismwas not shown to inﬂuence PFS, this study suggests that donor selection based on criteria other than
best HLAmatch is feasible and safe. This study opens the way for the future investigation of donor prioritization
based on promising non-HLA factors that may improve antitumor activity and decrease relapse after allo-BMT.
This study was registered at www.clinicaltrials.gov as NCT00946023.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION cell immunoglobulin-like receptor genotype have been shown
Relapse after allogeneic blood or bone marrow trans-
plantation (allo-BMT) remains a major challenge, and strate-
gies are needed that can enhance antitumor alloimmunity
without excess toxicity. Non-HLA factors such as donor killerdgments on page 2121.
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ty for Blood and Marrow Transplantation.to inﬂuence relapse rates and survival outcomes after unre-
lated donor BMT for acute leukemia [1]. However, such an
approach ideally requires the availability of several potential
donors to make selection feasible as well as clinical equipoise
in prioritizing non-HLA donor factors over the degree of HLA
matching. High-dose, post-transplantation cyclophosphamide
(PTCy) as graft-versus-host disease (GVHD) prophylaxis for
HLA-haploidentical (haplo), T cell-replete allo-BMT is associ-
atedwithacceptable ratesof acuteGVHD (aGVHD), nonrelapse
J.A. Kanakry et al. / Biol Blood Marrow Transplant 21 (2015) 2115e21222116mortality (NRM), and graft failure as well as low rates of
chronic GVHD (cGVHD), yielding results that appear
comparable with other alternative donor sources and even
HLA-matched relateddonors [2-11]. Allo-BMTusing PTCy thus
provides a platformuponwhich to investigate outcomeswhen
donors are selected based on factors other than best HLA
match.
FCGR3A is a low-afﬁnity immunoglobulin gamma Fc
receptor involved in natural killer cell-mediated antibody-
dependent cellular cytotoxicity and is mainly expressed on
natural killer cells. As compared with the FCGR3A-158FF (FF)
polymorphism, FCGR3A-158VV (VV) and to a lesser extent
FCGR3A-158VF (VF) have been associated with greater af-
ﬁnity to monoclonal antibodies and more favorable clinical
responses to rituximab [12-18]. We hypothesized that the
efﬁcacy of post-transplantation rituximab in patients with
B cell lymphoma might be enhanced if donors were selected
based on the afﬁnity of their FCGR3A-158 polymorphism for
rituximab as a means of enhancing a graft-versus-lymphoma
effect.
In this phase II prospective clinical trial of NMA,
related-donor allo-BMT using PTCy for patients with
relapsed/refractory B cell lymphoma, we integrated post-
transplantation rituximab and evaluated a donor selection
strategy prioritizing FCGR3A-158 polymorphisms over de-
gree of HLA matching. It was hypothesized that non-HLA
graft characteristics that might enhance antitumor activity
can be feasibly and safely prioritized over HLA matching and
that donor selection based on FCGR3A-158 polymorphisms
coupled with post-transplantation rituximab could improve
progression-free survival (PFS). Herein, we report the results
of what is, to our knowledge, the ﬁrst allo-BMT study where
donors were ﬁrst prioritized using a factor other than HLA
matching.
METHODS
Study Design
This was a single-center, prospective, phase II clinical trial approved by
the Johns Hopkins Institutional Review Board and conducted at the Sidney
Kimmel Comprehensive Cancer Center of Johns Hopkins Hospital (clinical-
trials.gov NCT00946023). Patients were enrolled between August 2009 and
April 2013. The primary objective was to determine the 1-year PFS, for the
cohort and by donor FCGR3A-159 polymorphism, of patients with B cell
lymphoma after NMA, related-donor allo-BMT using PTCy, integrated with
post-transplantation rituximab and the prioritization of donors having a
favorable FCGR3A-158 polymorphism. Predeﬁned secondary endpoints
included the feasibility of identifying and selecting donors with the more
favorable VV or VF FCGR3A-158 polymorphism, estimates of overall survival
(OS) and longer-term PFS, and estimates of the cumulative incidences of
relapse, nonrelapse mortality (NRM), aGVHD, and cGVHD. All patients gave
written informed consent both for donor selection based on FCGR3A-158
polymorphism status and for allo-BMT. Outcomes of all 83 patients trans-
planted on this clinical trial are presented.
Patients
Eligibility for allo-BMT included age  75 years old with a diagnosis of a
CD20(þ) B cell lymphoma with at least 1 related donor who was at a
minimum HLA haploidentical at the HLA-A, -B, -C, -DR, and -DQ alleles. For
low-grade B cell lymphomas or chronic lymphocytic leukemia/small lym-
phocytic lymphoma, patients had to have failed at least 2 prior therapies
excluding single-agent rituximab, progressed through multiagent chemo-
therapy, or undergone histologic transformation, unless the chronic lym-
phocytic leukemia/small lymphocytic lymphoma harbored an 11q or 17p
deletion. For aggressive B cell non-Hodgkin lymphoma or mantle cell lym-
phoma, patients had to have failed at least 1 prior multiagent chemotherapy
regimen. Patients were considered for allo-BMT after either failing a prior
autologous stem cell transplant or exhibiting disease features that made
cure with autologous transplant seem unlikely, such as history of chemo-
therapy refractoriness, short remission after prior chemotherapy, or histo-
logic transformation. For aggressive lymphomas, partial or complete
remission was required before allo-BMT. Patients with active centralnervous system involvement, HIV infection, or uncontrolled infection were
excluded. End-organ function requirements included left ventricular ejec-
tion fraction  35%, bilirubin  3.0 mg/dL, liver transaminases 5 times the
upper limit of normal, and forced expiratory volume in 1 second and forced
vital capacity  40% of predicted.
Donor Selection Algorithm
Donors were ﬁrst-degree relatives or half-related siblings who were at
least HLA-haploidentical, deﬁned as having a shared HLA haplotype be-
tween donor and patient at HLA-A, -B, -C, -DR, and -DQ based on allele or
allele-group level typing. Relatives with no known contraindication to
donation underwent FCGR3A-158 polymorphism testing. Suitable donors
were then prioritized as follows: (1) medically ﬁt to donate, (2) absence of
antidonor HLA antibodies, (3) VV polymorphism, (4) VF polymorphism, (5)
lack of major ABO incompatibility, (6) matched cytomegalovirus IgG
serostatus, (7) lack of minor ABO incompatibility, and (8) male donor pref-
erence for male patients. In cases of more than 1 potential VV donor (or VF
donor, in the absence of VV donors), HLA-matched donors were ﬁrst
prioritized over haplo donors and then donor age  18 was prioritized over
donor age < 18, with donors  70 preferred.
FCGR3A-158 Genotyping
The methods used for genotyping the FCGR3A-158 polymorphism of
patients and potential donors are provided as supplementary material (see
Supplementary Methods).
Transplantation Regimen
NMA conditioning consisted of ﬂudarabine, cyclophosphamide, and
200 cGy total body irradiation as previously described [5]. All grafts were
T-cell replete and bone marrow derived, with a target of 4  108 total
nucleated cells/kg of recipient ideal body weight. GVHD prophylaxis in all
cases consisted of high-dose PTCy (50 mg/kg/day i.v. on days þ3 and þ4),
mycophenolate mofetil on days þ5 through þ35, and tacrolimus starting
day þ5. In the absence of GVHD or graft failure, tacrolimus was continued
through day þ180 with goal trough of 5 to 15 ng/mL and then discontinued
without taper.
Supportive care measures were administered according to institutional
standards. Granulocyte colony-stimulating factors were given starting dayþ5
until the absolute neutrophil count (ANC) was 1000/mL for 3 days. Prophy-
lactic IV immunoglobulin G was permitted for hypogammaglobulinemia.
Rituximab 375 mg/m2 i.v. was scheduled once weekly for 8 weeks
starting on dayþ30 3 days, contingent on neutrophil recovery. The start of
rituximab was otherwise delayed. The rituximab schedule could also be
delayed or interrupted at physician discretion if there were concerns about
its safety, including severe unexplained cytopenias, active signiﬁcant
infection, or signiﬁcant GVHD. Rituximab was administered early after allo-
BMT because this is the period of highest relapse risk.
Deﬁnition of Endpoints
Disease status was deﬁned per standardized response criteria [19,20].
Patients with stable or progressive disease by the referenced criteria were
categorized as having “active disease” at the time of allo-BMT. Acute GVHD
was graded per the modiﬁed Keystone criteria [21]. Chronic GVHD was
evaluated using the National Institutes of Health Working Consensus
Criteria and Seattle criteria [22,23]. The Hematopoietic Cell Transplantation-
speciﬁc Comorbidity Index [24], Comorbidity-Age Index [25], and the
reﬁned Disease Risk Index [26] were retrospectively determined.
Neutrophil recovery was deﬁned as the ﬁrst of 3 consecutive days with
an ANC  500/mm3. Platelet recovery was deﬁned as the ﬁrst day with a
platelet count  20,000/mm3 without platelet transfusion in the preceding
week. Death before count recovery was considered a competing risk for
count recovery. Full donor chimerismwas deﬁned as95% donor cells in the
blood or bone marrow. Primary graft failure was deﬁned as <5% donor
chimerism by day þ60 in unsorted cells and/or CD3(þ) cells, without
detectable bone marrow malignancy. Secondary graft failure was deﬁned as
<5% donor chimerism after the initial presence of donor cells. Late-onset
neutropenia (LON) was deﬁned as an ANC  1000/mm3 (grade 3) or
500/mm3 (grade 4) starting 4 weeks after the last rituximab therapy
through 12 months after the last rituximab dose or until relapse [27,28].
Attribution of LON to rituximab is further described in the Results.
All time-to-event endpoints were measured from the date of allo-BMT.
PFS was the time to disease relapse, progression, unplanned treatment of
persistent disease, or death from any cause. OS was the time to death from
any cause. Competing risks for aGVHD and cGVHD included any PFS failure
or <5% donor chimerism from any cause. Relapse/progression and NRM
were considered competing risks. Patients without events were censored at
the date of their last evaluation.
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Differences in group characteristics were compared using the Fisher’s
exact test for categorical variables and the Kruskal-Wallis test for continuous
variables. PFS, disease-free survival, and OS were estimated using the
Kaplan-Meier method with 95% conﬁdence intervals (CIs) and compared
between groups using the log-rank statistic [29]. Cumulative incidences of
relapse, NRM, GVHD, and count recovery were estimated by competing risk
analysis using the method of Fine and Gray [30,31]. Two-sided P < .05 were
considered signiﬁcant. Data were analyzed using the R program, version
3.1.2 (R Foundation for Statistical Computing, Vienna, Austria, http://R-
project.org/). The dataset was locked for analysis on October 27, 2014.RESULTS
Patient Characteristics
Eighty-three consecutive patients with B cell lymphoma,
median age 59 years (range, 34 to 75), were transplanted on
this trial. Patient and transplant characteristics overall and
according to donor FCGR3A-158 polymorphism are summa-
rized in Table 1. Sixty-nine patients (83%) received haplo
grafts, and 14 patients (17%) received grafts from HLA-
matched related donors, with no difference by FCGR3A-158
donor polymorphism in the proportion receiving haplo
grafts. Diagnoses included de novo or transformed aggres-
sive non-Hodgkin lymphoma (59%), mantle cell lymphoma
(17%), and low-grade B cell malignancies (23%). Recipients of
haplo allo-BMT (n ¼ 69) had patient and transplantation
characteristics that were similar to the cohort as a whole
(Supplementary Table 1). Most patients (60%) had
intermediate-risk disease by the reﬁned Disease Risk Index,
which was similarly distributed across the donor FCGR3A-
158 polymorphism groups. More patients with a high
Comorbidity-Age Index received FF grafts (P ¼ .03).Donor Selection
The distribution of the FCGR3A-158 polymorphism among
patients was 11 VV (13%), 43 VF (52%), and 29 FF (35%). Of 270
donors tested for these polymorphisms (median donors
tested per patient, 3; range, 1 to 7), 35 (13%) had the VV
polymorphism, 121 (45%) were VF, 111 (41%) were FF, and 3
(1%) had unveriﬁed polymorphism results. From this, 54
patients (65%) were able to receive a VF or VV graft, of which
29 (54%) received a graft with a more favorable FCGR3A-158
polymorphism and 25 (46%) received a graft with the same
favorable VV (n ¼ 5) or VF (n ¼ 20) polymorphism. In 5 cases
(6%), a haplo donor was selected over a matched donor to use
a more favorable polymorphism. In 12 cases (14%), the per-
sonwith themost favorable polymorphismwas unsuitable to
donate, resulting in 5 cases (6%) where a donor with a less
favorable polymorphism than the recipient was used.Engraftment and Chimerism
The estimated cumulative incidence of neutrophil re-
covery was 98% (95% CI, 94% to 100%) by day þ30 (median,
16 days). The cumulative incidence of platelet recovery was
98% (95% CI, 94% to 100%) by day þ60 (median, 24 days). Of
81 assessable patients, primary graft failure occurred in 2
patients (2.5%), with autologous recovery of hematopoiesis
in both cases. Unsorted chimerism at dayþ60was 95% donor
or greater for 70 patients; an additional 10 patients had
mixed chimerism (5% to 94% donor cells) and 1 patient had
0% donor cells. CD3(þ) chimerism at dayþ60 was 95% donor
or greater for 69 patients, mixed for 9 patients, 0% for 2 pa-
tients, and not evaluated in 1 patient who was 100% donor in
unsorted blood. One patient with mixed chimerism on
dayþ60 developed secondary graft failure on dayþ112, withautologous hematopoietic recovery and ongoing disease-free
survival.
Toxicity
By competing risk analysis, the estimated probability of
NRM for the cohort was 5% (95% CI, 0% to 9%) at dayþ180 and
8% (95% CI, 2% to 14%) at 1 year (Figure 1A). Causes of NRM
(n¼ 12) were non-neutropenic infection (n¼ 5, with 3 in the
setting of GVHD treatment), neutropenic infection (n ¼ 3),
treatment-related myeloid neoplasm (n ¼ 2), pulmonary
embolism (n ¼ 1), and decompensated alcoholic cirrhosis
(n ¼ 1). At 1 year, the estimated probability of grades II to IV
aGVHD was 41% (95% CI, 30% to 52%), although most cases
were grade II with an estimated probability of grades III to IV
aGVHD at 1 year of 5% (95% CI, 0% to 9%) (Figure 1B). The
estimated probability of any cGVHD was 11% (95% CI, 4% to
18%) at 1 year and 14% (95% CI, 6% to 21%) at 2 years. The
estimated probability of systemic therapy for cGHVD was 9%
(95% CI, 2% to 15%) at 1 year and 10% (95% CI, 3% to 17%) at
2 years (Figure 1C).
Sixty-seven patients (81%) received all 8 planned doses of
post-transplantation rituximab. Reasons for fewer doses of
rituximab are outlined in Table 1. Grades 3 to 4 LON was
documented in 38 of 82 patients (46%) who received post-
transplantation rituximab, 25 (68%) of whom had minimal
or no associated clinical ﬁndings: 23 were completely
asymptomatic, 1 had oral ulcers requiring no therapy, and 1
required oral antibiotics for sinusitis. At the time of LON
diagnosis, 22 of 38 patients were assessed for donor
chimerism, of which 19 had 100% donor cells, 2 had mixed
chimerism (81% and 95% donor cells in unsorted peripheral
blood), and 1 had secondary graft failure. An additional 11
patients were not assessed for chimerism at the time of LON
but were assessed in the 1 months before or after LON; of
these, 10 had full donor chimerism on all assessments,
whereas 1 had 93% and 81% donor cells in the unsorted
peripheral blood in the 2 months before and after LON,
respectively.
By FCGR3A-158 polymorphism, there was no difference
detected in the percentage of patients with known grade 4
LON (P ¼ .79); the rates of hospitalization for serious grade 4
LON-associated infections and fatal infections were also
similar between groups. Thirteen patients (16%) were hos-
pitalized for grade 4 LON. Of those hospitalized, 6 patients
had LON that was likely not attributable to rituximab: 5
patients had neutropenia in the setting of multilineage
cytopenias during treatment for cytomegalovirus (n ¼ 4)
and/or GVHD (n ¼ 3), 1 of which was further complicated by
fatal adenovirus encephalitis, and 1 patient had pancyto-
penia in the setting of toxoplasmosis infection. Seven
patients were hospitalized with LON-associated infections
potentially attributable to rituximab, including 3 fatal in-
fections (1 Pseudomonas pneumonia, 1 presumed nocardio-
sis, and 1 presumed histoplasmosis).
Survival Outcomes and Relapse
The median follow-up was 2.6 years for all patients by the
reverse Kaplan-Meiermethod and 2.4 years (range,1.0 to 5.0)
among surviving patients. PFS, OS, and relapse point esti-
mates with 95% CIs are shown in Table 2. In the entire cohort,
the estimated rates of 1-year PFS and OS were 71% and 86%,
with corresponding 2-year probabilities of 60% and 76%
(Figure 1D). By competing risk analysis, the estimated 1-year
cumulative incidence of relapse for the cohort was 20% at
1 year and 27% at 2 years (Figure 1A).
Table 1
Patient and Transplantation Characteristics Overall and by Donor FCGR3A-158 Polymorphism
All Patients (n ¼ 83) VV Donor (n ¼ 17) VF Donor (n ¼ 43) FF Donor (n ¼ 23) P*
Patient age at BMT
Median, yr (range) 59 (34-75) 55 (38-69) 59 (34-75) 59 (40-75) .82
Age  60 39 (47%) 8 (47%) 20 (47%) 11 (49%) .99
Male sex 56 (67%) 12 (71%) 24 (56%) 20 (87%) .03
Disease
Aggressive lymphomay 49 (59%) 6 (35%) 31 (72%) 12 (52%)
MCL 13 (17%) 5 (29%) 4 (9%) 4 (17%)
CLL/SLLz 10 (12%) 2 (12%) 2 (5%) 6 (26%)
FL, grades 1-2 or MZLz 9 (11%) 3 (18%) 5 (12%) 1 (4%)
nLP HL 2 (2%) 1 (6%) 1 (2%) 0 (0%)
Disease status at allo-BMT .54
Complete remission 43 (52%) 12 (71%) 20 (47%) 11 (48%)
Partial remission 29 (35%) 4 (24%) 17 (40%) 8 (35%)
Active disease 11 (13%) 1 (6%) 6 (14%) 4 (17%)
Transformed lymphomax 22 (27%) 1 (6%) 14 (33%) 7 (30%) .10
Prior autografting 12 (14%) 4 (24%) 5 (12%) 3 (13%) .46
Reﬁned DRI .10
Low risk 28 (34%) 10 (59%) 10 (23%) 8 (35%)
Intermediate risk 50 (60%) 7 (41%) 30 (70%) 13 (57%)
High/Very high risk 5 (6%) 0 (0%) 3 (7%) 2 (9%)
HCT-CI score .12
0 (low risk) 17 (20%) 2 (12%) 12 (28%) 3 (13%)
1-2 (intermediate risk) 41 (49%) 12 (71%) 20 (47%) 9 (39%)
3 (high risk) 25 (30%) 3 (18%) 11 (26%) 11 (48%)
Comorbidity-Age Index .03
0-2 (low risk) 41 (49%) 10 (59%) 25 (58%) 6 (26%)
3 (high risk) 42 (51%) 7 (41%) 18 (42%) 17 (74%)
HLA matching .93
HLA-haploidentical 69 (83%) 14 (82%) 35 (81%) 20 (87%)
HLA-matchedk 14 (17%) 3 (18%) 8 (19%) 3 (13%)
Median donor age, yr (range) 41 (13-72) 41 (16-64) 42 (13-72) 42 (20-65) .78
Female into male 22 (27%) 3 (18%) 11 (26%) 8 (35%) .51
Patient CMV seropositive 30 (36%) 10 (59%) 15 (35%) 5 (22%) .06
CMV matching .30
Donor ()/recipient () 36 (43%) 4 (24%) 18 (42%) 14 (61%)
Donor (þ)/recipient (e) 17 (20%) 3 (18%) 10 (23%) 4 (17%)
Donor (e)/recipient (þ) 15 (18%) 5 (29%) 7 (16%) 3 (13%)
Donor (þ)/recipient (þ) 15 (18%) 5 (29%) 8 (19%) 2 (9%)
Infused cell dose, median (range)
TNC  108/kg 4.5 (2.2-7.7) 4.5 (3.1-6.1) 4.3 (2.2-7.7) 4.6 (3.2-6.1)
CD34þ cells  106/kg 4.5 (1.8-25.1) 4.1 (1.8-25.1) 4.7 (2.1-9.8) 4.4 (2.1-8.6)
CD3þ cells  107/kg 4.1 (1.6-10.4) 5.1 (2.3-6.8) 3.7 (1.6-10.4) 4.1 (2.8-9.7)
Doses of post-BMT rituximab .92
8 67 (81%) 15 (88%) 34 (79%) 18 (78%)
6-7{ 8 (10%) 2 (12%) 4 (9%) 2 (9%)
4-5{ 4 (5%) 0 (0%) 3 (7%) 1 (4%)
1-3{ 3 (4%) 0 (0%) 2 (5%) 1 (4%)
0# 1 (1%) 0 (0%) 0 (0%) 1 (4%)
MCL indicates mantle cell lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; FL, follicular lymphoma; MZL, marginal zone
lymphoma; nLP HL, nodular lymphocyte predominant Hodgkin lymphoma; DRI, disease risk index; HCT-CI, hematopoietic cell transplantespeciﬁc comorbidity
index; CMV, cytomegalovirus; TNC, total nucleated cells.
* Probability values are for differences between the 3 FCGR3A polymorphism groups.
y Diffuse large B cell lymphoma (DLBCL) de novo (n ¼ 16) or transformed (n ¼ 21), T cell/histiocyte-rich large B cell lymphoma (n ¼ 2), primary mediastinal
large B cell lymphoma (n ¼ 2), FL grade 3 (n ¼ 8).
z Excluding transformed lymphoma.
x Transformation was deﬁned as evolution of a low-grade lymphoma into an aggressive lymphoma, including transformation of FL grades 1-2 into FL grade 3.
Changes from FL grade 3 to DLBCL were not considered a transformation. Transformations included DLBCL out of low-grade lymphoma (n ¼ 21) and aggressive
B cell lymphoma not otherwise speciﬁed out of CLL (n ¼ 1).
k Including 2 patients who received grafts from genetically haplo donors who were phenotypically 10/10 HLA-matched.
{ Reasons that 1-7 doses of rituximab were given: unconﬁrmed (n ¼ 4), neutropenia (n ¼ 2), GVHD (n ¼ 2), musculoskeletal pains (n ¼ 2), death before
completion of rituximab (n ¼ 2), inadequate intravenous access (n ¼ 1), graft failure (n ¼ 1), relapse (n ¼ 1).
# Rituximab not given because of early death before neutrophil recovery.
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Point estimates for relapse, PFS, and OS for subgroups are
shown in Table 2. By donor FCGR3A-158 polymorphism, the
1-year estimated cumulative incidence of relapsewas 18% for
VV, 23% for VF, and 17% for FF grafts (Figure 2A). The esti-
mated 1-year PFS was 82%, 70%, and 65% for VV, VF, and FF
grafts, respectively (Figure 2B, log-rank P ¼ .44), with
corresponding estimated 1-year OS of 94%, 86%, and 78%,log-rank P ¼ .43. The estimated 1-year probability of NRM
was 0% (95% CI, 0% to 0%) for VV, 7% (95% CI, 0% to 15%) for VF,
and 17% (95% CI, 1% to 33%) for FF.
Among those receiving haplo grafts (n ¼ 69), the 1-year
estimated cumulative incidence of relapse was 20%
(Figure 3A, with NRM; Table 2). The estimated rates of 1-year
PFS and OS were 70% and 83%, respectively, with corre-
sponding 2-year probabilities of 63% and 73% (Figure 3B,
Figure 1. Overall outcomes of NMA, related-donor BMT with post-transplantation high-dose cyclophosphamide and rituximab (N ¼ 83). (A) Relapse and NRM by
competing risk analysis. (B) aGVHD (grades II to IV and III to IV) by competing risk analysis. (C) cGVHD (overall and requiring systemic therapy) by competing risk
analysis. (D) PFS and OS. Of these 83 patients, 69 received HLA-haploidentical grafts.
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45% (95%CI, 33% to57%), grades III to IV aGVHDwas6% (95%CI,
0% to 11%), cGVHDwas 13% (95% CI, 5% to 21%), and NRMwas
10% (95% CI, 3% to 17%) for those receiving haplo grafts.
DISCUSSION
Hereinwe report the outcomes of a phase II study of NMA,
related-donor allo-BMT for B cell lymphomas incorporating
PTCy, post-transplantation rituximab, and donor selection
based on FCGR3A-158 polymorphism. The PFS and OS wereTable 2
Point Estimates for Relapse, PFS, and OS for the Cohort and Subgroups
Group Probability (%)
Relapse PF
1 Year 2 Year 1 Y
All patients (N ¼ 83) 20 (13-28) 27 (17-37) 71
Aggressive NHL (n ¼ 49) 22 (11-34) 25 (12-37) 69
Haplo (n ¼ 69) 20 (11-30) 23 (13-34) 70
VV or VF donor (n ¼ 60) 22 (11-32) 29 (17-41) 73
VV donor (n ¼ 17) 18 (0-36) 25 (3-46) 82
VF donor (n ¼ 43) 23 (10-36) 31 (17-45) 70
FF donor (n ¼ 23) 17 (1-33) 22 (4-39) 65
NHL indicates non-Hodgkin lymphoma.
Values in parentheses are 95% CIs. There were no statistically signiﬁcant differen
Disease-free survival was virtually identical to PFS and is therefore not shown sepfavorable for the cohort as a whole and appear improved as
compared with the historical outcomes of patients with
B cell lymphomas who received NMA haplo allo-BMT using
PTCywithout rituximab, where the estimated 1-year PFS rate
is lower at around 50%, based on our published and unpub-
lished data [5]. The survival outcomes presented here are
also consistent with other recent reports using post-
transplantation rituximab, suggesting that this approach
may improve disease control after allo-BMT [32,33]. Our
study is unique given the use of haplo grafts in most patientsS OS
ear 2 Year 1 Year 2 Year
(62-82) 60 (52-70) 86 (78-93) 76 (67-86)
(58-84) 62 (49-78) 86 (76-96) 74 (62-88)
(60-81) 63 (52-76) 83 (74-92) 73 (63-84)
(63-85) 62 (50-76) 88 (81-97) 79 (69-90)
(66-100) 68 (48-96) 94 (84-100) 87 (71-100)
(56-85) 59 (46-76) 86 (76-97) 76 (64-90)
(44-88) 56 (39-81) 78 (63-97) 69 (52-91)
ces in relapse, PFS, or OS according to donor FCGR3A-158 polymorphism.
arately.
Figure 2. Outcomes of NMA, related-donor BMT according to donor FCGR3A-158 polymorphism. (A) Relapse by competing-risk analysis. (B) PFS.
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on non-HLA factors.
In a recently published prospective phase II trial of NMA
HLA-matched allo-BMT for B cell lymphoma with pre- and
post-transplantation rituximab, the 2-year event-free survival
and OS probabilities were similar to ours at 72% and 78%,
respectively [32]. Because these data were not available in
planning the trial, we had not anticipated such good survival
outcomes. The overall favorable outcomes virtually precluded
ﬁnding signiﬁcant differences based on FCGR3A-158 poly-
morphism. The potential beneﬁts of FCGR3A-158-guided
donor selection might be further obscured if such beneﬁts are
associated only with particular subtypes of B cell lymphoma
or are associated with only particular regimens as has been
suggested [15,17,34].
LONwas documented in nearly half of our patients, as has
been shown by others [32]. However, it can be difﬁcult to
attribute neutropenia to rituximab versus other etiologies
(eg, infection) in the allo-BMT setting. Importantly, LON was
asymptomatic in most patients, and the use of post-
transplantation rituximab did not appear to translate into
an increased risk of severe infection.
The favorable PFS and OS, as well as low relapse rates,
suggest that post-transplantation rituximab may have a
direct antitumor effect or modulate graft-related antitumor
immune effects. With regard to the latter, we note that theFigure 3. Outcomes of NMA, related HLA-haploidentical donor BMT (n ¼ 6incidence of grades II to IV aGVHD in the present study
appears higher than has previously been reported for NMA
haplo-BMT with PTCy but no rituximab. However, this was
attributable to higher rates of grade II aGVHD, with rates of
grades III to IV aGVHD that were not higher than previous
reports [5,6,8,10]. Because the principal difference between
the platform in prior studies and the current study is the
inclusion of post-transplantation rituximab here, this sug-
gests that rituximab may impact aGVHD risk. Although
there is evidence to support the role of post-transplantation
rituximab in preventing or treating cGVHD [35-42], less is
known about how rituximab might inﬂuence aGVHD risk
[43]. The cellular interactions mediating aGVHD and cGVHD
are complicated, and the relative roles of donor and host
B cells, including lymphoma cells, in GVHD pathogenesis
are incompletely understood. We hypothesize that
rituximab-induced killing of lymphoma cells early after
allo-BMT promotes the immunogenic cross-presentation of
lymphoma-derived minor histocompatibility and tumor
antigens to nontolerant donor T cells, thereby augmenting
both aGVHD and the graft-versus-lymphoma effect,
respectively [44]. However, other interpretations of our
data are certainly possible.
Of broader signiﬁcance, this study demonstrates the
feasibility and safety of selecting related donors based on
factors other than degree of HLA matching. The haplo9). (A) Relapse and NRM by competing risk analysis. (B) PFS and OS.
J.A. Kanakry et al. / Biol Blood Marrow Transplant 21 (2015) 2115e2122 2121outcomes presented here are similar to those previously
published for matched related or unrelated donor allo-BMT
[2,7]. The relatively low rates of grades III to IV aGVHD,
cGVHD requiring systemic therapy, graft failure, and NRM
with haplo grafts suggest that HLA matching need no longer
be a barrier to optimal donor selection. This study provides
support for future trials that similarly aim to identify and
select donors based on factors apart from HLA that are hy-
pothesized to improve the antitumor activity of the graft and
decrease relapse after allo-BMT.
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